Antibody functionalized targeted siRNA nanodelivery epigenetically controls Slug-Vimentin cross-talk for...

Area of Science:

• Oncology
• Nanotechnology
• Epigenetics

Background:

• Neuroblastoma (NB) is an aggressive extracranial cancer driven by epigenetic alterations.
• Bmi1 is a key epigenetic regulator in NB progression.
• Current epigenetic therapies face challenges in targeted delivery and efficacy.

Purpose of the Study:

• To develop a targeted epigenetic therapy for NB using a novel nanodelivery system.
• To investigate the therapeutic potential of anti-GD2 decorated Bmi1 siRNA encapsulated HSA-Chitosan nanohybrids.
• To elucidate the molecular mechanisms underlying the anti-cancer effects.

Main Methods:

• Encapsulation of Bmi1 siRNA within HSA-Chitosan nanohybrids.
• Decoration of nanohybrids with anti-GD2 antibodies for targeted delivery.
• Evaluation of transfection and knockdown efficiency in NB models.
• Assessment of anti-tumor and anti-metastatic effects in vitro and in vivo.
• Analysis of the Bmi1-mediated Sox2/Slug/Vimentin signaling pathway.

Main Results:

• The nanohybrids demonstrated efficient transfection and significant Bmi1 knockdown.
• Targeted delivery via anti-GD2 decoration enhanced therapeutic efficacy.
• Remarkable inhibition of tumor growth and cell migration was observed.
• Downregulation of vimentin indicated anti-metastatic activity.
• The study identified Bmi1-mediated Sox2/Slug/Vimentin signaling as a key pathway inhibited by the nanohybrids.

Conclusions:

• HSA-Chitosan nanohybrids serve as a promising nucleic acid delivery system for NB.
• Anti-GD2 decorated nanohybrids offer targeted epigenetic therapy for neuroblastoma.
• This approach shows significant potential for treating NB by inhibiting key oncogenic signaling pathways.